What is Apnimed?
Apnimed is dedicated to discovering, developing, and commercializing innovative oral therapies for sleep-related breathing diseases, with a primary focus on obstructive sleep apnea (OSA). Its lead candidate, AD109, targets the neuromuscular dysfunction responsible for airway collapse during sleep, aiming to provide an alternative to current device-based or surgical treatments. The company's mission is to broaden access to effective diagnosis and treatment for individuals affected by OSA and similar conditions, positioning itself as a key player in the sleep medicine sector.
How much funding has Apnimed raised?
Apnimed has raised a total of $380.3M across 6 funding rounds:
Series A
$15M
Series B
$25M
Series C
$142.3M
Debt
$23M
Private Equity
$25M
Debt
$150M
Series A (2020): $15M, investors not publicly disclosed
Series B (2021): $25M led by Tao Capital Partners , LLC, Morningside Venture Capital, and Seligman Investments
Series C (2023): $142.3M supported by Alpha Wave Ventures, Seligman Investments, Morningside Venture Capital, Sectoral Asset Management, Nexpoint Residential Trust, and Tao Capital Management
Debt (2025): $23M, investors not publicly disclosed
Private Equity (2026): $25M, investors not publicly disclosed
Debt (2026): $150M with participation from HealthCare Royalty Management
Key Investors in Apnimed
Morningside Venture Capital
Morningside Venture Capital, established in 1986, is a private equity and venture capital firm that specializes in early-stage technology company investments, with a focus on making strategic investments in promising ventures.
Sectoral Asset Management
Sectoral Asset Management is an investment advisor focused on global equities within the healthcare sector, offering expertise in public and private equity strategies, particularly in biotech.
HealthCare Royalty Management
HealthCare Royalty Management provides capital solutions to biopharmaceutical companies through royalty acquisitions and tailored financing, supporting innovation in the life sciences industry.
What's next for Apnimed?
With significant enterprise-level funding and a recent strategic investment, Apnimed is poised for advanced clinical development and potential regulatory submissions. The company's trajectory suggests a focus on scaling operations, advancing its pipeline through late-stage trials, and preparing for market entry. Future strategic collaborations and capital infusions will likely support its efforts to expand the reach of its innovative treatments for sleep-related breathing disorders.
See full Apnimed company page
